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Abstract 
The aim of this work was to evaluate the effects of BM-567 (N-pentyl-N'-[(2-cyclohexylamino-5-
nitrobenzene)sulfonyl]urea), a torasemide derivative, on both thromboxane A2 (TXA2) receptors (TP) and 
thromboxane synthase of human platelets. The drug affinity for TP receptors of human washed platelets has been 
determined. In this test, BM-567 showed a high affinity (IC50: 1.1±0.1 nM) for the TP receptors in comparison 
with BM-531 (IC50: 7.8 ±0.7 nM) and sulotroban (IC50: 931±85 nM), two TXA2 antagonists. We also 
demonstrated that BM-567 prevented platelet aggregation induced by arachidonic acid (AA) (600 µM) (ED100: 
0.20 ± 0.10 µM), U-46619, a stable TXA2 agonist (1 µM) (ED50: 0.30 ± 0.04 µM) and collagen (1 µg ml-1) (% of 
inhibition: 44.3 ± 4.3% at 10 µM) and inhibited the second wave of ADP (2 µM). Moreover, when BM-567 was 
incubated in whole blood from healthy donors, the closure time measured by the Platelet Function analyzer 
(PFA-100®) was significantly prolonged (closure time: 215 ± 21 s) by using collagen/epinephrine cartridges. 
Finally, at the concentration of 1 µM, BM-567 completely reduced the TXB2 production from human platelets 
stimulated with AA (600 µM). These results indicate that BM-567 is a novel combined TXA2 receptor antagonist 
and thromboxane synthase inhibitor characterized by a powerful antiplatelet potency. 
1. INTRODUCTION 
Platelet activation and vasoconstriction are intimately involved in thrombus formation. In particular, 
thromboxane A2 (TXA2), which causes platelet aggregation and vasoconstriction, plays an important role in the 
process of vascular thrombosis [1-6]. 
TXA2 is a biologically potent arachidonate metabolite derived from the cyclo-oxygenase pathway [7]. Indeed, 
TXA2 is formed by the action of thromboxane synthase on the prostaglandin endoperoxide H2 (PGH2) [8] mainly 
in activated platelets and macrophages [9,10]. Initially, there was a great interest in the potential use of TXA2 
receptor (TP) antagonists such as sulotroban. However, these compounds were too selective to completely 
inhibit platelet aggregation. In general, interest has switched to agents which are combined receptor antagonists 
and thromboxane synthase inhibitors such as ridogrel . The rationale behind this is that the TP receptor 
antagonist activity can block the aggregatory and vasoconstrictor actions of PGH2 accumulating after inhibition 
of thromboxane synthesis and that this endoperoxide can be converted to either prostaglandin D2 (PGD2) by the 
platelets or prostacyclin (PGI2) by the vessel wall, both of which increase platelet cyclic AMP levels to inhibit 
platelet activation [5] (Fig. 1). 
According to the observation that the pyridinic sulfonylurea torasemide, a high ceiling loop diuretic, was able to 
induce a concentration-dependent relaxation of the canine coronary artery precontracted with the stable 
carboxylic TXA2 [11], we designed and synthesized a series of its derivatives. Among these drugs, BM-500 (N-
isopropyl-N'-[(2-metatoluyl-amino-5-nitrobenzene)sulfonyl]urea) emerged as one of the most potent TXA2 
receptor antagonists of this   generation   [12]. Later, we developed   BM-531 (N-tert-butyl-N'-[(2-
cyclohexylamino-5-nitrobenzene) sulfonyl]urea) which was demonstrated to be a stronger TXA2 receptor 
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antagonist than BM-500 and to combine a thromboxane synthase inhibitory activity [13,14]. These encouraging 
results led us to design a new generation of derivatives chemically related to BM-531. Therefore, we selected 
BM-567 and examined its effects on TP receptors and thromboxane synthase of human platelets (Fig. 2). Its 
affinity for TXA2 receptors has been determined and its antiaggregatory potency has been evaluated by its ability 
to prevent human platelet aggregation induced by arachidonic acid (AA), U-46619, a stable TXA2 agonist, ADP 
and collagen. Moreover, we measured the activity of this drug on primary hemostasis measured by the Platelet 
Function Analyzer (PFA-100®). Finally, we examined the effects of BM-567 on TXB2 production from platelets 
stimulated with AA in order to evaluate the thromboxane synthase inhibitory potency. 
Fig. 1. Prostaglandins and thromboxane biosynthesis. 
 
2. MATERIALS AND METHODS 
2.1.  Drugs and chemicals 
Drugs were synthesized according to general synthetic pathways previously described [12,15]. Drug mother 
solutions were prepared in dimethylsulfoxide (DMSO). The final concentration of DMSO did not exceed 0.1%, a 
concentration which did not affect the parameters measured. Stock solutions of sodium arachidonate (5mM; 
Sigma, Belgium) were prepared in water. U-46619 (Cayman Chemical, Ann Arbor, MI) supplied in ethanolic 
solution was diluted with the incubation buffer. SQ-29548 was purchased from RBI (Bioblock, Illkirch, France)   
and sulotroban was synthesized according to a general procedure previously described [16]. The solution of 
collagen was provided by Horm (France) and [5,6-3H]SQ-29548 (46 Ci mmol-1) was obtained from NEN 
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Fig. 2. Chemical structures of torasemide, BM-500, BM-531 and BM-567. 
 
2.2. Pharmacology 
Platelet binding. The binding test realized on human washed platelets was performed according to a previously 
described method [13,14]. Human platelet-rich plasma (PRP) was provided by the Belgian Red Cross. Fractions 
(10 ml) of this plasma were centrifuged for 10 min at 1000 g (4°C). The supernatant was discarded, the pellet 
resuspended in NaCl (0.2%, 5 ml), mixed for 20 s and then diluted with NaCl (1.6%, 5 ml). The suspension was 
centrifuged again for 5min at 1000 g (4°C). The supernatant was removed and the pellet was suspended in 
calcium- and magnesium-free Tyrode-Hepes buffer (mM: NaCl 137, KCl 2.7, NaH2PO4 0.4, NaHCO3 12, D-
glucose 5, Hepes q.s. ad pH 7.4) to a concentration of 2 x 108 cells ml-1. Freshly prepared samples of this 
suspension (500 µl) were incubated with [5,6-3H]SQ-29548 (5nM final concentration, 100µl) for 60min at 25°C. 
The displacement was initiated by addition of the studied ligand dissolved in the same buffer (400µl). After 
incubation (30min, 25°C), ice-cold Tris-HCl buffer (10 mM, pH 7.4; 4ml) was added and the sample was rapidly 
filtered through a glass-fiber filter (Whatman GF/C) and the tube was rinsed twice with ice-cold buffer (4 ml). 
The filters were then placed in plastic scintillation vials containing an emulsion-type scintillation mixture (4 ml) 
and the radioactivity was counted. The amount of [5,6-3H]SQ-29548 specifically bound to the human platelet TP 
receptors (Bs, %) was calculated: 
Bs = 100 x (B-NSB)/(Bt-NSB) (1) 
where Bt (total binding) and NSB (non-specific binding) are the radioactivity of [5,6-3H]SQ-29548 (5 nM) bound 
to the platelets incubated in the absence of any competing ligand and in the presence of unlabelled SQ-29548 (50 
µM), respectively. B is the radioactivity of the filtered platelets incubated with [5,6-3H]SQ-29548 (5 nM) and the 
studied compound at a fixed concentration of 10-6M or at concentrations ranging from 10-5 to 10-10M. In each 
experiment, NSB varied between 5% and 7% of Bt. For the most potent drugs, three concentration-response 
curves were measured in triplicate using concentrations ranging from 10-5 to 10-10 M. The concentration of drug, 
which reduced the amount of specifically bound [5,6-3H]SQ-29548 by 50% (IC50), was determined for each drug 
by non-linear regression analysis (GraphPad Prism software). The results are expressed as mean ± SDM. 
Platelet aggregation. The antiplatelet potency was determined according to a previously described method [13]. 
Briefly, blood was collected by venipuncture from volunteers reported to be free from medication for at least 10 
days and diluted (9:1) with trisodium citrate (3.8% w/w) in a polypropylene tube. The PRP was obtained from 
the supernatant fraction after centrifugation for 20min at 90 g (25°C). The remaining blood was centrifuged at 
2000 g for 5min (25°C) and the supernatant gave the platelet-poor plasma (PPP). The platelet concentration of 
PRP was adjusted to 3 x 108 cells ml-1 by dilution with PPP. Aggregation tests were performed according to 
Born's turbidimetric method [19] by means of two-channel aggregometer (Chrono-log®). PPP was used to adjust 
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the photometric measurement to the minimum optical density. PRP (225 µl) was added in a silanized cuvette and 
stirred (1100 rev min-1). Drug solution (20 µl) was then added and the mixture was incubated at 37°C for 3min. 
Platelet aggregation was initiated by addition of (5 µl) AA (600 µM final), U-46619 (l µM final) ADP (2 µM 
final) and collagen (l µg ml-1 final). To evaluate platelet aggregation, the maximum increase in light transmission 
was determined from the aggregation curve 6min after addition of the inducer. The drug concentration 
preventing 100% of the platelet aggregation induced by AA (ED100) was measured and expressed as mean ± 
SDM (n = 3). The drug concentration reducing 50% of the platelet aggregation induced by U-46619 (ED50) was 
calculated by non-linear regression analysis from at least three dose-response curves. The results are expressed 
as mean + SDM. 
PFA-100. The PFA-100 system® (Dade Behring International®) has been described elsewhere in detail [17]. 
The system consists of an instrument and a disposable test cartridge where primary hemostasis is stimulated. 
Briefly, the system monitors platelet aggregation on a collagen-epinephrine-coated membrane as whole blood 
sample is aspirated under controlled flow conditions through a microscopic aperture cut into the membrane. The 
time required for the platelet plug to occlude the aperture is indicative of the platelet function in the sample. 
Blood samples collected by venipuncture from four healthy volunteers reported to be free from medication for at 
least 10 days and diluted (9:1) with trisodium citrate (3.8% w/w) in a polypropylene tube were incubated with or 
without the drug (10 µM) prior to test at room temperature typically for 5min with occasional mixing by gentle 
inversion. Then, the blood sample is added to the sample reservoir, and the test cartridge is added into the PFA-
100® and incubated at 37°C. The sample is aspirated through a central aperture (150 µM diam.) cut into the 
membrane under steady vacuum created by displacement of the piston of a syringe pump connected to the 
vacuum chuck. Platelet activation and aggregation occurs at the area surrounding the aperture due to the 
presence of agonists and local shear conditions, eventually leading to complete occlusion of the aperture. The 
instrument monitors blood flow through the aperture and reports the time required for occlusion of the aperture 
by the platelet plug, thus defining the closure time (CT). The CT measured are expressed as mean + SDM (n = 
4). 
Thromboxane synthase activity. PRP preparation is identical to that described for the platelet aggregation 
experiments. Each drug was dissolved in dimethylsulfoxide (DMSO) and diluted with a Tyrode-Hepes buffer 
(mM: NaCl 137, KC1 2.7, NaH2PO4·-H2O 0.4, D-glucose 5, NaHCO3 12, Hepes; pH 7.4). To 900 ml of PRP, 50 
ml NaCl, 0.9% and 10 ml of drug solution were added. After 6min incubation at 37°C under stirring (600 rpm), 
aggregation was induced by 40 ml sodium arachidonate (0.6 mM). After 4min, the reaction was stopped by 
adding 50 ml of indomethacin (0.02 M in ethanol). The sample was immediately centrifuged (17 500 g for 10 s) 
and the supernatant was removed and frozen (-78°C) until assayed for TXB2. Basal and maximal production of 
TXB2 was estimated in the absence and in the presence of AA, respectively. Thromboxane synthase activity was 
expressed as the TXB2 production, which was measured by using a competitive enzyme immunoassay (TXB2 
EIA Kit, Cayman Chemical Company). 
3. RESULTS 
In a first experimentation, we evaluated the affinity of BM-567 for human platelet TP receptors. Thereby, we 
measured the capacity of our drug to displace [5,6-3H]SQ-29548, a potent competitive ligand of TP receptors, 
from its binding site on human washed platelets. We realized concentration-response curves and calculated IC50 
values, which represent the drug concentration, needed to displace 50% of [5,6-3H]SQ-29548 from TP receptors. 
Table 1 shows that BM-567 (IC50: 1.1±0.1 nM) is characterized by a higher affinity than sulotroban (IC50: 931 ± 
85nM), BM-500 (IC50: 79 ± 7.9nM) and BM-531 (IC50: 7.8 ± 0.7nM). 
In a second step, we determined the property of BM-567 to prevent human platelet aggregation induced by AA 
(600 µM), U-46619 (1 µM), ADP (2 µM) and collagen (lµgml-1). When AA was used as inducer, BM-567 
totally prevented the aggregation at the lower dose of 0.20 ± 0.10 µM (ED100)· Compared to the other TXA2 
receptor antagonists referenced in Table 1, BM-567 was much more active than both sulotroban (ED100: 10.2 ± 
2.1 µM) and BM-500 (ED100: 14.0 ± 2.3µM) and no significant difference was found in comparison with BM-
531 (ED100: 0.125 ± 0.015 µM). When the TXA2 stable agonist U-46619 was used as platelet aggregating agent, 
BM-567 (ED50: 0.30 ± 0.04 µM) was slightly more active than BM-531 in terms of ED50, which correspond to 
the concentration required preventing 50% of the aggregation. It was nevertheless much more potent than BM-
500 and sulotroban (ED50: 9.5 ± 2.4 and 11.3 ± 4.1 µM, respectively). The same ranking can be made when 
collagen was used as platelet aggregating agent. Indeed, at the concentration of 10 µM, BM-567 and BM-531, 
respectively, prevented 44.3 ± 4.3% and 42.9 ± 49% of platelet aggregation while BM-500 and sulotroban were 
not active. Finally, when ADP was used as inducer, none of the tested drugs prevented the initial phase of 
aggregation. On the other hand, BM-500 and sulotroban (10 µM) weakly prevented the second wave of platelet 
Published in : Prostaglandins Leukotrienes and Essential Fatty Acids (2003), vol.68, iss.1, pp.49-54 
Status: Postprint (Author’s version) 
aggregation while at the same concentration both BM-567 and BM-531 completely inhibited this secondary 
phase of ADP-induced aggregation. In this aggregometry study, torasemide (100 µM) was inactive, irrespective 
of the inducer used (Table 1). 
The antiplatelet potency of BM-567 has been confirmed on human whole blood by measuring with the platelet 
function analyzer (PFA-100®). In this study, we examined the effects of BM-567 on primary hemostasis. 
Compared to reference values (CT: 110±10 s), torasemide, BM-500 and sulotroban did not modify closure time 
of the central aperture of a membrane coated with a mixture of collagen and epinephrine (CT: 108 ± 9; 114 ± 8; 
112±5 s, respectively) while both BM-531 and BM-567 significantly prolonged CT (CT: 175 ± 24 and 215 ± 21 
s, respectively). 
Finally, we examined the effects of BM-567 on the thromboxane synthase activity from human platelets. At the 
concentrations of 10 and 1 µM, BM-567 totally prevented the production of TXB2 by human platelets activated 
by AA (600 µM). At the same dosage, the thromboxane synthase inhibitor furegrelate reduced the production of 
TXB2 from 67.52% while torasemide and BM-500 showed no inhibitory potency. At lower concentration (0.1 
µM), BM-567 did not inhibit the production of TXB2 anymore. In this test, BM-531 showed the same inhibitory 
profile as BM-567 (Fig. 3). 
4. DISCUSSION AND CONCLUSIONS 
In 1992, Uchida et al. [11] demonstrated that torasemide elicited a dose-dependent vasodilating action in the 
isolated canine coronary arteries contracted by the carbocyclic thromboxane A2 (CTA2), a stable analogue of the 
potent coronary vasoconstrictor TXA2, whereas indapamide or furosemide had little effect on this preparation. 
Nevertheless, these effects were observed at non-therapeutic doses. In a previous work, we confirmed that 
torasemide possessed a weak affinity for TXA2 receptor of human washed platelets and that this potency was not 
strong enough to prevent platelet aggregation induced by AA, U-46619, collagen and ADP, even at the dose of 

















Sulotroban 931 ± 85 10.2 ± 2.1 11.3 ± 4.1 NI 112 ± 5 
Torasemide 2691± 72 > 100 >100 NI 108 ± 9 
BM-500 79 ± 7.9 14 ± 2.3 9.5 ± 2.4 NI 114 ± 8 
BM-531 7.8 ± 0.7 0.125 ± 0.015 0.48 ± 0.09 42.9 ± 4.9 175 ± 24 
BM-567 1.1 ± 0.1 0.20 ± 0.10 0.30 ± 0.04 44.3 ± 4.3 215 ± 21 
a Drug affinity for TXA2 receptor of human platelet: IC50 represents the drug concentrations needed to displace 50% of [5,6-3H]SQ-29548 
from TXA2 receptor of human washed platelets. 
b Drug concentrations required preventing 100% of the platelet aggregation induced by 600 µM of AA. 
c Drug concentrations required preventing 50% of the platelet aggregation induced by 1 µM of U-46619. 
d
 Inhibition percentage of platelet aggregation induced by collagen with a 10 µM drug prevention (NI = no inhibition). 
e
 Closure times measured by PFA-100® (with drugs used at 10 µM) compared to reference value (110 ± 10 s). Results are expressed as mean 
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Fig. 3. Effects of furegrelate and BM-567 on thromboxane B2 production induced by human platelets which 
expresses the thromboxane synthase inhibitory activity. 
 
This work led to a first generation of TXA2 receptor antagonist of which BM-500 was the most active. These 
encouraging results led us to design and synthesize a series of torasemide derivatives of second generation 
represented by BM-531, which was demonstrated as the first combined thromboxane receptor antagonist and 
thromboxane synthase inhibitor belonging to the sulfonylurea class. Finally, with the aim of improving the 
pharmacological profile of BM-531, we designed different other derivatives of which BM-567 emerged. Indeed, 
we demonstrated that BM-567 strongly displaced [5,6-3H]SQ-29548 from TXA2 receptor of human washed 
platelets with a higher potency than BM-500, BM-531 and sulotroban. We also confirmed its powerful TXA2 
antagonism and antiplatelet potency using standard  aggregometric  techniques  and  the  recently developed 
platelet function analyzer (PFA-100®). In these tests, BM-567 was at least as active as BM-531, while BM-500 
and sulotroban were less potent. Finally, we confirmed that BM-567 also reduced the production of TXB2 by 
human platelets. This effect cannot be attributed to a cyclo-oxygenase inhibition since we demonstrated that BM-
567 did not prevent the prostaglandin E2 (PGE2) production induced by both ovine COX-1 and COX-2 
separately incubated with AA. This result confirms the thromboxane synthase inhibitory activity of BM-567. 
This has the advantage that other AA metabolites can still be produced. Thus, in the setting of platelet activation, 
as would occur locally at a vascular injury site, the platelet-produced endoperoxides can be taken up by other 
cells (smooth muscle cells, endothelial cells and white blood cells) which can then produce PGI2 and other 
antithrombotic prostanoids [18,19]. Therefore, the antithrombotic effect due to the presence of locally produced 
prostacyclin could exceed that expected by only blocking TP receptors. Additionally, the conversion of the 
endoperoxides to E-type prostaglandins could help to reduce thrombus formation due to their vasodilatory 
action. A variety of compounds with both activities have been reported. Ridogrel was the first putative dual 
inhibitor of TXA2 to be tested clinically, but it yielded disappointing clinical results because its receptor affinity 
(IC50: 1.7 µM) was demonstrated too weak in regards to its thromboxane inhibitory (IC50: 0.004 µM) effects to 
adequately qualify as a compound with a dual mode of action [20]. This is not the case with BM-567 which 
exhibits a combined activity on both TP receptors and thromboxane synthase at a similar concentration range. 
BM-567 was found slightly more active than BM-531 in preventing platelet aggregation induced by U-46619 
and prolonging closure time with collagen-epinephrine cartridges from PFA-100®. From a structural point of 
view, both drugs feature an acidic sulfonylurea moiety which appears to mimic the carboxylic acid function 
found in all prostanoids and the majority of their pharmacological modulators [21]. In conclusion, this work led 
to the discovery of BM-567, an original, well-balanced non-carboxylic TXA2 receptor antagonist and 
thromboxane synthase inhibitor. This compound has been selected for further in vivo experiments as 
antithrombotic agent. 
Acknowledgements 
This work was support by grants of the "La Communauté Française de Belgique". 
 
Published in : Prostaglandins Leukotrienes and Essential Fatty Acids (2003), vol.68, iss.1, pp.49-54 
Status: Postprint (Author’s version) 
References 
[1] P. Saldeen, I. Nilsson, T. Saldeen, Increased synthesis of thromboxane B2 and 6 keto-PGFlα in hand veins 
from patients with deep venous thrombosis, Thromb. Res. 32 (1983) 461-67. 
[2] D. Fitzgerald, L. Roy, F. Catella, G. FitzGerald, Platelet activation in unstable coronary disease, N. Engl. J. 
Med. 315 (1986) 983-989. 
[3] T. Saldeen, P. Saldeen, W. Nichols, D. Lawson, F. Nicolini, J. Mehta, Increased production of thromboxane 
A2 by coronary arteries after thrombolysis, Am. Heart J. 125 (1993) 277-284. 
[4] K. Schror, Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and 
prophylaxis, Semin. Thromb. Hemost. 23 (1997) 349-356. 
[5] J.M. Dogne, X. de Levai, J. Delarge, J.L. David, B. Masereel, New trends in thromboxane, prostacyclin 
modulators, Curr. Med. Chem. 7 (2000) 609-628. 
[6] F. Catella-Lawson, Vascular biology of thrombosis: platelet-vessel wall interactions and aspirin effects, 
Neurology 57 (2001) S5-7. 
[7] M. Hamberg, J. Svensson, B. Samuelsson, Thromboxanes: a new group of biologically active compounds 
derived from prostaglandin endoperoxides, Proc. Natl. Acad. Sci. USA 72 (1975) 2994-2998.  
[8] P. Needleman, S. Moncada, S. Bunting, J. Vane, M. Hamberg, B. Samuelsson, Identification of an enzyme in 
platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides, Nature 261 (1976) 
558-560.  
[9] E. Ellis, O. Oelz, L. Roberts, N. Payne, B. Sweetman, A. Nies, J. Oates, Coronary arterial smooth muscle 
contraction by a substance released from platelets: evidence that it is thromboxane A2, Science 193 (1976) 1135-
1137. 
[10] N. Pawlowski, G. Kaplan, A. Hamill, Z. Cohn, W. Scott, Arachidonic acid metabolism by human 
monocytes. Studies with platelet-depleted cultures, J. Exp. Med. 158 (1983) 393-112. 
[11] T. Uchida, H. Kido, K. Yamanaga, M. Okita, M. Watanabe, A novel loop diuretic, torasemide, inhibits 
thromboxane A2-induced contraction in the isolated canine coronary artery, Prostaglandins Leukot. Essent. Fatty 
Acids 45 (1992) 121-124. 
[12] B. Masereel, J. Damas, J. Fontaine, M. Lembèche, F. Lacan, A. Nuhrich, J. Delarge, L. Pochet, J.-M. 
Dogné, Thromboxane A2 receptor antagonism in man and in rat by a sulfonylcyano-guanidine (BM-144) and a 
sulfonylurea (BM-500), J. Pharm. Pharmacol. 51 (1999) 695-701. 
[13] J.M. Dogne, X. de Levai, P. Neven, S. Rolin, J. Wauters, J.L. David, J. Delarge, B. Massereel, Effects of a 
novel non-carboxylic thromboxane A2 receptor antagonist (BM-531) derived from torasemide on platelet 
function, Prostaglandins Leukot Essent Fatty Acids 62 (5) (2000) 311-317. 
[14] J.M. Dogne, S. Rolin, X. de Levai, P. Benoit, P. Neven, J. Delarge, P. Kolh, J. Damas, J.L. David, B. 
Masereel, Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531, 
Cardiovasc. Drug Rev. 19 (2) (2001) 87-96. 
[15] J.M. Dogne, J. Wouters, S. Rolin, C. Michaux, L. Pochet, F. Durant, J. Delarge, B. Masereel, Design, 
synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A2 receptor antagonist and 
thromboxane synthase inhibitor, J. Pharm. Pharmacol. 53 (5) (2001) 669-680. 
[16] A. Nuhrich, M. Varache-Lembèche, F. Lacan, G. Devaux, Use of infrared spectroscopy in monitoring a new 
method for the preparation of sulotroban, antithrombotic drug, J. Chem. Educ. 73 (1996) 1185-1189. 
[17] S. Kundu, E. Heilmann, R. Sio, C. Garcia, R. Davidson, R. Ostgaard, Description of an in vitro platelet 
function analyzer-PFA-100, Semin. Thromb. Hemost. 21 (suppl. 2) (1995) 106-112. 
Published in : Prostaglandins Leukotrienes and Essential Fatty Acids (2003), vol.68, iss.1, pp.49-54 
Status: Postprint (Author’s version) 
[18] P. Gresele, J. Arnout, H. Deckmyn, E. Huybrechts, G. Pieters, J. Vermylen, Role of proaggregatory and 
antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and 
thromboxane receptor antagonism, J. Clin. Invest. 80 (1987) 1435-1445. 
[19] D.H. Hechtman, M.H. Kroll, M.A. Gimbrone Jr., A.I. Schafer, Platelet interaction with vascular smooth 
muscle in synthesis of prostacyclin, Am. J. Physiol. 260 (1991) H1544-H1551. 
[20] R. Soyka, B.D. Guth, H.M. Weisenberger, P. Luger, T.H. Muller, Guanidine derivatives as combined 
thromboxane A2 receptor antagonists and synthase inhibitors, J. Med. Chem. 42 (7) (1999) 1235-1249. 
[21] C. Michaux, S. Rolin, J.M. Dogne, F. Durant, B. Masereel, J. Delarge, J. Wouters, Structure determination 
and comparison of BM567, a sulfonylurea, with terbogrel, two compounds with dual action, thromboxane 
receptor antagonism and thromboxane synthase inhibition, Bioorg. Med. Chem. Lett. 11 (8) (2001) 1019-1022. 
